玻璃体腔阿柏西普与玻璃体切除联合全视网膜光凝治疗增殖性糖尿病视网膜病变玻璃体出血的随机临床试验
这项多中心随机临床试验纳入205例增殖性糖尿病视网膜病变玻璃体出血患者,比较初始玻璃体腔阿柏西普注射与玻璃体切除联合全视网膜光凝的疗效。研究可能把握度不足。
核心结论
- 初始阿柏西普与玻璃体切除联合全视网膜光凝在24周平均视力字母评分上无统计学显著差异。
- 研究可能把握度不足,无法排除初始手术的临床重要获益。
研究设计与样本
- 随机临床试验,在美国和加拿大39个DRCR Retina Network中心进行。
- 每例患者一眼随机分配至阿柏西普组(100眼)或玻璃体切除联合全视网膜光凝组(105眼)。
- 阿柏西普组初始接受4次每月注射,两组随访中可按方案标准接受阿柏西普或玻璃体切除。
主要发现
- 23个次要结局中15个无显著差异。
- 2年内阿柏西普组33眼(33%)接受玻璃体切除,手术组34眼(32%)接受后续阿柏西普。
临床怎么用
- 对于增殖性糖尿病视网膜病变玻璃体出血,初始阿柏西普或玻璃体切除联合全视网膜光凝均可考虑。
- 需注意手术组早期视力恢复更快,但长期视力结局无显著差异。
局限性
- 研究可能把握度不足,无法检测初始手术的临床重要获益。
- 95%CI范围较宽,不能排除组间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vitreous hemorrhage from proliferative diabetic retinopathy can cause loss of vision. The best management approach is unknown. OBJECTIVE: To compare initial treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation for vitreous hemorrhage from proliferative diabetic retinopathy. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 39 DRCR Retina Network sites in the US and Canada including 205 adults with vison loss due to vitreous hemorrhage from proliferative diabetic retinopathy who were enrolled from November 2016 to December 2017. The final follow-up visit was completed in January 2020. INTERVENTIONS: Random assignment of eyes (1 per participant) to aflibercept (100 participants) or vitrectomy with panretinal photocoagulation (105 participants). Participants whose eyes were assigned to aflibercept initially received 4 monthly injections. Both groups could receive aflibercept or vitrectomy during follow-up based on protocol criteria. MAIN OUTCOMES AND MEASURES: The primary outcome was mean visual acuity letter score (range, 0-100; higher scores indicate better vision) over 24 weeks (area under the curve); the study was powered to detect a difference of 8 letters. Secondary outcomes included mean visual acuity at 4 weeks and 2 years. RESULTS: Among 205 participants (205 eyes) who were randomized (mean [SD] age, 57 [11] years; 115 [56%] men; mean visual acuity letter score, 34.5 [Snellen equivalent, 20/200]), 95% (195 of 205) completed the 24-week visit and 90% (177 of 196, excluding 9 deaths) completed the 2-year visit. The mean visual acuity letter score over 24 weeks was 59.3 (Snellen equivalent, 20/63) (95% CI, 54.9 to 63.7) in the aflibercept group vs 63.0 (Snellen equivalent, 20/63) (95% CI, 58.6 to 67.3) in the vitrectomy group (adjusted difference, -5.0 [95% CI, -10.2 to 0.3], P = .06). Among 23 secondary outcomes, 15 showed no significant difference. The mean visual acuity letter score was 52.6 (Snellen equivalent, 20/100) in the aflibercept group vs 62.3 (Snellen equivalent, 20/63) in the vitrectomy group at 4 weeks (adjusted difference, -11.2 [95% CI, -18.5 to -3.9], P = .003) and 73.7 (Snellen equivalent, 20/40) vs 71.0 (Snellen equivalent, 20/40) at 2 years (adjusted difference, 2.7 [95% CI, -3.1 to 8.4], P = .36). Over 2 years, 33 eyes (33%) assigned to aflibercept received vitrectomy and 34 eyes (32%) assigned to vitrectomy received subsequent aflibercept. CONCLUSIONS AND RELEVANCE: Among participants whose eyes had vitreous hemorrhage from proliferative diabetic retinopathy, there was no statistically significant difference in the primary outcome of mean visual acuity letter score over 24 weeks following initial treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation. However, the study may have been underpowered, considering the range of the 95% CI, to detect a clinically important benefit in favor of initial vitrectomy with panretinal photocoagulation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02858076.
引用
- Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020. PMID: 33320223. doi:10.1001/jama.2020.23027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。